Nektar Therapeutics CEO Howard Robin's 2018 pay falls 26% to $13M
Nektar Therapeutics reports 2018 executive compensation
By ExecPay News
Published: April 30, 2019
Nektar Therapeutics reported fiscal year 2018 executive compensation information on April 30, 2019.
In 2018, five executives at Nektar Therapeutics received on average a compensation package of $6.8M, a 26% decrease compared to previous year.
Average pay of disclosed executives at Nektar Therapeutics
Howard W. Robin, Chief Executive Officer, received $13M in total, which decreased by 26% compared to 2017. 42% of Robin's compensation, or $5.6M, was in option awards. Robin also received $1.6M in non-equity incentive plan, $969K in salary, $5M in stock awards, as well as $98K in other compensation.
Jillian B. Thomsen, Chief Accounting Officer, received a compensation package of $6.2M. 72% of the compensation package, or $4.5M, was in stock awards.
Gil M. Labrucherie, Chief Financial Officer, earned $5.7M in 2018, a 26% decrease compared to previous year.
Stephen K. Doberstein, Chief Research and Development Officer, received $4.8M in 2018, which decreases by 37% compared to 2017.
Maninder Hora, Senior Vice President Pharmaceutical Development and Chief Technical Operations Officer, earned $3.8M in 2018, a 18% decrease compared to previous year.
Related executives
Howard Robin
Nektar Therapeutics
Chief Executive Officer
Gil Labrucherie
Nektar Therapeutics
Chief Financial Officer
Stephen Doberstein
Nektar Therapeutics
Chief Research and Development Officer
Maninder Hora
Nektar Therapeutics
Senior Vice President Pharmaceutical Development and Chief Technical Operations Officer
Jillian Thomsen
Nektar Therapeutics
Chief Accounting Officer
You may also like
Source: SEC filing on April 30, 2019.